Literature DB >> 15288396

Hyperalgesia in an animal model of multiple sclerosis.

Sue A Aicher1, Marc B Silverman, Clayton W Winkler, Bruce F Bebo.   

Abstract

Many individuals with multiple sclerosis (MS) experience clinically significant pain, yet the underlying neural mechanisms for MS pain are not understood. Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that mimics many clinical and pathological features of MS, including central nervous system inflammation and demyelination. To determine whether EAE is an appropriate model for MS-related pain, nociceptive responses in both male and female SJL mice were measured before and after immunization with myelin proteolipid protein peptide 139-151 (PLP(139-151)) in complete Freund's adjuvant to induce 'active' EAE. To determine if changes in nociception were due to direct effects of encephalitogenic T cells, nociceptive responses in female SJL mice were measured following the transfer of activated, PLP(139-151) specific T cells to induce 'passive' EAE. Both forepaw and tail withdrawal latencies to a radiant heat stimulus were measured. In both active and passive EAE, there was an initial increase in tail withdrawal latency (hypoalgesia) that peaked several days prior to the peak in motor deficits during the acute disease phase. During the chronic disease phase, tail withdrawal latencies decreased and were significantly faster than control latencies for up to 38 days post-immunization. This hyperalgesia was seen in both sexes and in both active and passive EAE models. Forepaw withdrawal latencies remained within 1-2 s of baseline latencies for the entire testing period, indicating that the hypoalgesia and hyperalgesia were most pronounced in clinically affected body regions. These results suggest that both active and passive EAE are useful models of MS-related pain.

Entities:  

Mesh:

Year:  2004        PMID: 15288396     DOI: 10.1016/j.pain.2004.03.025

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  29 in total

Review 1.  Chemokines: integrators of pain and inflammation.

Authors:  Fletcher A White; Sonia K Bhangoo; Richard J Miller
Journal:  Nat Rev Drug Discov       Date:  2005-10       Impact factor: 84.694

2.  CaMKIIα Mediates the Effect of IL-17 To Promote Ongoing Spontaneous and Evoked Pain in Multiple Sclerosis.

Authors:  Xiaoyu Hu; Fang Huang; Zaijie Jim Wang
Journal:  J Neurosci       Date:  2017-11-16       Impact factor: 6.167

3.  Temporal pattern of plasma membrane calcium ATPase 2 expression in the spinal cord correlates with the course of clinical symptoms in two rodent models of autoimmune encephalomyelitis.

Authors:  Arnaud Nicot; Michael Kurnellas; Stella Elkabes
Journal:  Eur J Neurosci       Date:  2005-05       Impact factor: 3.386

4.  Regulatory T Cells and Their Derived Cytokine, Interleukin-35, Reduce Pain in Experimental Autoimmune Encephalomyelitis.

Authors:  Samuel S Duffy; Brooke A Keating; Chamini J Perera; Justin G Lees; Ryan S Tonkin; Preet G S Makker; Pascal Carrive; Oleg Butovsky; Gila Moalem-Taylor
Journal:  J Neurosci       Date:  2019-01-16       Impact factor: 6.167

Review 5.  Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain.

Authors:  N Percie du Sert; A S C Rice
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 6.  Pain and multiple sclerosis: pathophysiology and treatment.

Authors:  Claudio Solaro; Erika Trabucco; Michele Messmer Uccelli
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

7.  IL-1β Is Involved with the Generation of Pain in Experimental Autoimmune Encephalomyelitis.

Authors:  David Henrique Rodrigues; Bruno Pereira Leles; Vivian Vasconcelos Costa; Aline Silva Miranda; Daniel Cisalpino; Dawidson Assis Gomes; Danielle Glória de Souza; Antônio Lúcio Teixeira
Journal:  Mol Neurobiol       Date:  2015-11-28       Impact factor: 5.590

8.  Elevation of tumor necrosis factor α in dorsal root ganglia and spinal cord is associated with neuroimmune modulation of pain in an animal model of multiple sclerosis.

Authors:  F Begum; W Zhu; C Cortes; B MacNeil; M Namaka
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-14       Impact factor: 4.147

9.  Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy.

Authors:  Evan Sloane; A Ledeboer; W Seibert; B Coats; M van Strien; S F Maier; K W Johnson; R Chavez; L R Watkins; L Leinwand; E D Milligan; A M Van Dam
Journal:  Brain Behav Immun       Date:  2008-09-20       Impact factor: 7.217

10.  Mechanisms and pharmacology of neuropathic pain in multiple sclerosis.

Authors:  T Iannitti; B J Kerr; B K Taylor
Journal:  Curr Top Behav Neurosci       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.